Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro
– Pre-NDA Meeting to discuss requirements for a 505(b)(2) NDA submission for IkT-001Pro in up to eight blood and stomach cancer indications –
– Bioequivalence to 400 mg and 600 mg imatinib mesylate completed with minimal adverse events –
Related news for (IKT)
- Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
- Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity
- inhibikase therapeutics announces closing of up to $275 million financing and advancement of ikt-001pro into a late stage clinical trial in pulmonary arterial hypertension
- inhibikase therapeutics announces pricing of $110 million private placement to advance ikt-001pro, an optimized prodrug of imatinib, into a late-stage trial in pulmonary arterial hypertension
- 24/7 Market News Snapshot 09 October, 2024 – Inhibikase Therapeutics, Inc. Common Stock (NASDAQ:IKT)